Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05510245 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT05510245 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 18 participants.
The verdict
NCT05510245, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects of kidney functional impairment may have on the study medicine (PF-07081532). People with certain level of kidney functional impairment may process PF-07081532 differently from healthy people. PF-07081532 is developed as a potential treatment for type II diabetes. Participants will take the study medicine as a tablet by mouth once at the study clinic and then will stay at the study clinic for about 7 days. During that time, the study team will monitor their treatment experience and take some blood samples to test the level of PF-07081532. This will help us understand if certain degree of kidney functional impairment will have an effect on the study medicine PF-07081532.
Interventions
- DRUG PF-07081532
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2023-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05510245
The ClinicalTrials.gov registry entry for NCT05510245 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-07081532 is the first listed.
NCT05510245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05510245 about?
NCT05510245 is a clinical study titled "A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction". The purpose of this study is to understand the effects of kidney functional impairment may have on the study medicine (PF-07081532). People with certain level of kidney functional impairment may process PF-07081532 differently from healthy people. PF-07081532 is developed as a potential treatment fo...
What is the current status of trial NCT05510245?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2022-08-29. Estimated completion is 2023-07-20.
What interventions are being tested in trial NCT05510245?
The interventions under investigation include: PF-07081532 (DRUG).
Who is sponsoring clinical trial NCT05510245?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.